Hal Barron Leaves GSK With A Stronger Pipeline But Still Awaiting Inflection
R&D Spending Still Lags Behind Peers
Research chief Barron is departing before his turnaround of GSK is fully realized but the consumer division spin-out could unlock new R&D money to help it challenge the sector’s leaders.
You may also be interested in...
As Barron departs for new rejuvenation-focused biotech Altos Labs, GSK will be under pressure to ensure its R&D can continue to produce green shoots.
Sanofi’s monoclonal antibody is still expected to lead the market in respiratory syncytial virus, but Pfizer may have just overturned expectations about maternal vaccination with its product.
Bepirovirsen made the hepatitis B virus undetectable in nearly 30% of patients in a Phase II study – but it remains to be seen whether this response be sustained once treatment with the novel antisense product ends.